Exogenous acquisition of Pseudomonas aeruginosa in intensive care units: a prospective multi-centre study (DYNAPYO study).


Journal

The Journal of hospital infection
ISSN: 1532-2939
Titre abrégé: J Hosp Infect
Pays: England
ID NLM: 8007166

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 03 06 2019
accepted: 06 08 2019
pubmed: 17 8 2019
medline: 12 11 2020
entrez: 17 8 2019
Statut: ppublish

Résumé

Pseudomonas aeruginosa remains one of the most common nosocomial pathogens in intensive care units (ICUs). Although exogenous acquisition has been widely documented in outbreaks, its importance is unclear in non-epidemic situations. To elucidate the role of exogenous origin of P. aeruginosa in ICU patients. A chronological analysis of the acquisition of P. aeruginosa was performed using samples collected in 2009 in the DYNAPYO cohort study, during which patients and tap water were screened weekly. Molecular relatedness of P. aeruginosa isolates was investigated by pulsed-field gel electrophoresis. Exogenous acquisition was defined as identification of a P. aeruginosa pulsotype previously isolated from another patient or tap water in the ICU. The DYNAPYO cohort included 1808 patients (10,402 samples) and 233 water taps (4946 samples). Typing of 1515 isolates from 373 patients and 375 isolates from 81 tap water samples identified 296 pulsotypes. Analysis showed exogenous acquisition in 170 (45.6%) of 373 patients. The pulsotype identified had previously been isolated from another patient and from a tap water sample for 86 and 29 patients, respectively. The results differed according to the ICU. Exogenous acquisition of P. aeruginosa could be prevented in half of patients. The overall findings of this survey support the need for studies on routes of transmission and risk assessment approach to better define how to control exogenous acquisition in ICUs.

Sections du résumé

BACKGROUND BACKGROUND
Pseudomonas aeruginosa remains one of the most common nosocomial pathogens in intensive care units (ICUs). Although exogenous acquisition has been widely documented in outbreaks, its importance is unclear in non-epidemic situations.
AIM OBJECTIVE
To elucidate the role of exogenous origin of P. aeruginosa in ICU patients.
METHODS METHODS
A chronological analysis of the acquisition of P. aeruginosa was performed using samples collected in 2009 in the DYNAPYO cohort study, during which patients and tap water were screened weekly. Molecular relatedness of P. aeruginosa isolates was investigated by pulsed-field gel electrophoresis. Exogenous acquisition was defined as identification of a P. aeruginosa pulsotype previously isolated from another patient or tap water in the ICU.
FINDINGS RESULTS
The DYNAPYO cohort included 1808 patients (10,402 samples) and 233 water taps (4946 samples). Typing of 1515 isolates from 373 patients and 375 isolates from 81 tap water samples identified 296 pulsotypes. Analysis showed exogenous acquisition in 170 (45.6%) of 373 patients. The pulsotype identified had previously been isolated from another patient and from a tap water sample for 86 and 29 patients, respectively. The results differed according to the ICU.
CONCLUSION CONCLUSIONS
Exogenous acquisition of P. aeruginosa could be prevented in half of patients. The overall findings of this survey support the need for studies on routes of transmission and risk assessment approach to better define how to control exogenous acquisition in ICUs.

Identifiants

pubmed: 31419468
pii: S0195-6701(19)30320-2
doi: 10.1016/j.jhin.2019.08.008
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

40-45

Informations de copyright

Copyright © 2019 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Auteurs

M Coppry (M)

Université de Bordeaux, CHU Bordeaux, Hygiène hospitalière, Bordeaux, France; Université de Bordeaux, Inserm, Bordeaux Population Health Research Centre, UMR 1219, France. Electronic address: maider.coppry@chu-bordeaux.fr.

C Leroyer (C)

CHU Bordeaux, Hygiène hospitalière, Bordeaux, France.

M Saly (M)

CHU Bordeaux, Hygiène hospitalière, Bordeaux, France.

A-G Venier (AG)

Université de Bordeaux, Inserm, Bordeaux Population Health Research Centre, UMR 1219, France; CHU Bordeaux, CPIAS Nouvelle-Aquitaine, Bordeaux, France.

C Slekovec (C)

CHU Besançon, Hygiène hospitalière, Besançon, France.

X Bertrand (X)

CHU Besançon, Hygiène hospitalière, Besançon, France.

S Parer (S)

CHU Montpellier, Hygiène hospitalière, Montpellier, France.

S Alfandari (S)

CH Tourcoing, Réanimation et maladies infectieuses, Tourcoing, France.

E Cambau (E)

CHU Lariboisière, AP-HP, Hygiène hospitalière, Paris, France.

B Megarbane (B)

CHU Lariboisière, AP-HP, Réanimation médicale, Paris, France.

C Lawrence (C)

CHU Poincaré, AP-HP, Hygiène hospitalière, Garches, France.

B Clair (B)

CHU Poincaré, AP-HP, Réanimation médicale, Garches, France.

A Lepape (A)

CHU Lyon Sud, Réanimation médicale, Lyon, France.

P Cassier (P)

CHU Lyon Hôpital E. Herriot, Laboratoire d'hygiène, Lyon, France.

D Trivier (D)

CH Lens, Hygiène hospitalière, Lens, France.

A Boyer (A)

Université de Bordeaux, CHU Bordeaux, Réanimation médicale, Bordeaux, France.

H Boulestreau (H)

CHU Bordeaux, Hygiène hospitalière, Bordeaux, France.

J Asselineau (J)

CHU Bordeaux, Service d'information médicale, Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique, Bordeaux, France.

V Dubois (V)

Université de Bordeaux, CHU Bordeaux, Laboratoire de bactériologie, Bordeaux, France; Université de Bordeaux, UMR 5234 CNRS, Université de Bordeaux, Bordeaux, France.

R Thiébaut (R)

Université de Bordeaux, Inserm, Bordeaux Population Health Research Centre, UMR 1219, France; CHU Bordeaux, Service d'information médicale, Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique, Bordeaux, France.

A-M Rogues (AM)

Université de Bordeaux, CHU Bordeaux, Hygiène hospitalière, Bordeaux, France; Université de Bordeaux, Inserm, Bordeaux Population Health Research Centre, UMR 1219, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH